Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View Item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Thumbnail
View/Open
Accepted version (1.275Mb)
Publication Date
2017-07
ICR Author
Houlston, Richard
Pawlyn, Charlotte
Author
Rasche, L
Angtuaco, E
McDonald, JE
Buros, A
Stein, C
Pawlyn, C
Thanendrarajan, S
Schinke, C
Samant, R
Yaccoby, S
Walker, BA
Epstein, J
Zangari, M
van Rhee, F
Meissner, T
Goldschmidt, H
Hemminki, K
Houlston, R
Barlogie, B
Davies, FE
Morgan, GJ
Weinhold, N
Type
Journal Article
Metadata
Show full item record
Abstract
<sup>18</sup>F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging with background signal suppression (DWIBS) are 2 powerful functional imaging modalities in the evaluation of malignant plasma cell (PC) disease multiple myeloma (MM). Preliminary observations have suggested that MM patients with extensive disease according to DWIBS may be reported as being disease-free on FDG-PET ("PET false-negative"). The aim of this study was to describe the proportion of PET false-negativity in a representative set of 227 newly diagnosed MM patients with simultaneous assessment of FDG-PET and DWIBS, and to identify tumor-intrinsic features associated with this pattern. We found the incidence of PET false-negativity to be 11%. Neither tumor load-associated parameters, such as degree of bone marrow PC infiltration, nor the PC proliferation rate were associated with this subset. However, the gene coding for hexokinase-2, which catalyzes the first step of glycolysis, was significantly lower expressed in PET false-negative cases (5.3-fold change, <i>P</i> < .001) which provides a mechanistic explanation for this feature. In conclusion, we demonstrate a relevant number of patients with FDG-PET false-negative MM and a strong association between hexokinase-2 expression and this negativity: a finding which may also be relevant for clinical imaging of other hematological cancers.
URL
https://repository.icr.ac.uk/handle/internal/4274
Collections
  • Cancer Therapeutics
  • Genetics and Epidemiology
Licenseref URL
http://www.rioxx.net/licenses/all-rights-reserved
Version of record
10.1182/blood-2017-03-774422
Subject
Humans
Multiple Myeloma
Hexokinase
Fluorodeoxyglucose F18
Neoplasm Proteins
False Positive Reactions
Positron-Emission Tomography
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Female
Male
Research team
Myeloma Biology and Therapeutics
Cancer Genomics
Language
eng
Date accepted
2017-04-13
License start date
2017-07
Citation
Blood, 2017, 130 (1), pp. 30 - 34

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.